Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma
- On July 11, 2025, Guangzhou Concord Cancer Center completed China’s first proton therapy for choroidal malignant melanoma.
- Guangzhou Concord Cancer Center uses advanced pencil beam scanning and real-time image guidance for effective treatment.
- This treatment offers a new option to avoid enucleation, the standard procedure for choroidal malignant melanoma.
- Guangzhou Concord Cancer Center is the first in China to provide this eye-preserving treatment option.
Insights by Ground AI
Does this summary seem wrong?
43 Articles
43 Articles
4
10
3

+41 Reposted by 41 other sources
Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong…
Coverage Details
Total News Sources43
Leaning Left4Leaning Right3Center10Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 24%
C 59%
R 18%
Factuality
To view factuality data please Upgrade to Premium